Coverage
Every drug, mapped.
DrugIQ reconciles India's drug record — canonical entities at brand, molecule, formulation and strength — against a fixed list of authoritative global references. This page lists what's in the canonical layer today, where the data comes from, and where we are still building out.
What's covered per record
Where the data comes from
REGULATORS
CDSCO Indian licensing · NPPA price notifications · NLEM 2022 + DPCO 2013 statutory ceilings · FDA · EMA · PMDA global cross-reference
GUIDELINES
CPIC pharmacogenomic recommendations · ICMR India clinical guidance · WHO Essential Medicines · NCCN oncology
SAFETY
FAERS US adverse events · EudraVigilance EU · VigiBase WHO global
Active investment areas
DrugIQ launched as an AI-reviewed canonical layer with deep statutory and regulatory coverage. The following areas are where we are continuously densifying the record. Per-area completion rates published at v1 launch.
Drug ↔ manufacturer canonical link
Joining every drug to its canonical company entity, enabling cross-rail queries (drug + device + biologic from the same manufacturer).
Clinical metadata depth
Expanding indications, contraindications, dosing tables and drug-drug interactions per record.
PGX coverage expansion
Currently strongest in cardiovascular and oncology drug-gene pairs. Expanding into psychiatry, infectious disease, and pain management.
Regional pricing variants
State-level price ceilings (TNMSC, KSMSCL) and PMBJP Jan Aushadhi rates.
Refresh cadence